

1 **Viral load dynamics in asymptomatic and symptomatic patients during Omicron**

2 **BA.2 outbreak in Shanghai, China, 2022: a longitudinal cohort study**

3 Jingwen Ai^{1†}, Jiaxin Zhou^{2†}, Yang Li^{1†}, Feng Sun^{1†}, Shijia Ge^{1†}, Haocheng Zhang^{1†},

4 Yanpeng Wu², Yan Wang², Yilin Zhang¹, Hongyu Wang¹, Jianpeng Cai¹, Xian Zhou¹,

5 Sen Wang¹, Rong Li¹, Zhen Feng¹, Xiangyanyu Xu², Xuemei Yan², Yuchen Zhao²,

6 Juanjuan Zhang^{2,3}, Hongjie Yu^{1,2*}, Wenhong Zhang^{1,3*}

7

8 **Affiliations:**

9 1. Department of Infectious Diseases, Shanghai Key Laboratory of Infectious

10 Diseases and Biosafety Emergency Response, National Medical Center for Infectious

11 Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, China

12 2. School of Public Health, Fudan University, Key Laboratory of Public Health Safety,

13 Ministry of Education, Shanghai, China

14 3. Shanghai Huashen institute of microbes and infections. Shanghai, China

15

16 **Running title:** Viral load dynamics in COVID-19 patients

17

18 **Corresponding authors:**

19 Hongjie Yu, yhj@fudan.edu.cn

20 Wenhong Zhang, zhangwenhong@fudan.edu.cn

21 †These authors contributed equally.

22 *These authors were joint senior authors contributed equally to this work.

23

24 Word count (abstract): 247

25 Word count (main text): 3121

26

27 **Abstract**

28 **Backgrounds:**

29 The SARS-CoV-2 virus has caused global outbreaks, including the recent Omicron BA.2
30 wave in Shanghai in spring 2022. While, the viral load dynamic of Omicron infections with
31 different clinical severity was still unclear.

32

33 **Methods:**

34 A prospective cohort was conducted on 48,830 hospitalized COVID-19 patients in three
35 hospitals in Shanghai, China, from 23 March and 15 May 2022. Regular nucleic acid testing
36 was performed and the Cycle threshold (Ct) value tested by RT-PCR was used as a proxy of
37 viral load. The viral load dynamic by different clinical severity since initial detection and the
38 risk factors were analyzed.

39

40 **Results:**

41 The study included 31% asymptomatic cases, 68% mild-moderate cases, 1% severe cases,
42 1.29% critical and fatal cases. 57% of patients tested positive upon admission, average Ct
43 value remained stable with peak viral concentrations occurring at 4 days (median Ct value of
44 27.5), followed by a decrease with a viral shedding time (VST) of 6.1 days (IQR, 4.0-8.8 days).
45 Omicron viral load varied by age and clinical severity, but peak Ct values occurred at similar
46 times. Unvaccinated status, age over 60, and comorbidities were associated with higher peak
47 viral concentrations and longer shedding durations. Asymptomatic cases had a 40%
48 contagious probability within 6 days of detection. Mild-moderate cases and severe cases had
49 a 27%, >50% probability of infectiousness post-symptom resolution, respectively.

50

51 **Conclusion:**

52 The initial Ct value could forecast severe consequences. Unvaccinated older people with
53 specific comorbidities are the high-risk groups associated with high viral load and long
54 shedding duration.

55

56 **Key words:**

57 COVID-19; Omicron; BA.2; Viral load dynamics; Viral shedding time

58 **Background**

59 Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory
60 syndrome coronavirus 2 (SARS-CoV-2), has resulted in unprecedented impact worldwide.
61 Viral load, as a key determinant of viral shedding, is shown to correlate with infectivity,
62 transmissibility, and pathogenicity. Understanding the SARS-CoV-2 viral load trajectory is
63 crucial for developing epidemiological control strategies and optimizing clinical management
64 of COVID-19 patients. The cycle threshold (Ct) value obtained by reverse
65 transcription-polymerase chain reaction (RT-PCR) was widely used as a surrogate marker for
66 infectiousness due to high correlation between RNA viral load and the presence of infectious
67 virus¹.
68 Since March 2022, a local outbreak of the Omicron sub-lineage BA.2^{2,3} had occurred in
69 Shanghai, resulting in over 0.6 million laboratory-confirmed infections of early June⁴. While
70 previous studies have revealed some viral load characteristics of ancestral SARS-CoV-2 and
71 other variants of concern (VOC)⁵⁻¹⁰, Omicron variant has shown dramatic changes in viral
72 dynamics and clinical features. Some previous studies mainly focused on the effect of
73 vaccines on viral dynamics of Omicron or only analyzed in-depth the viral dynamics of
74 symptomatic patients¹¹⁻¹⁵. Several studies included asymptomatic individuals but the size
75 numbers were limited^{14,16} or only presented the viral shedding time¹⁷. One study analyzed the
76 viral dynamics in detail focused on mild cases¹⁵. Evidences about peak viral load and viral
77 shedding dynamics of Omicron are still sparse and there is a lack of multicenter evidence of

78 viral dynamics on a broad spectrum of diseases including asymptomatic, mild and severe and
79 death cases supporting by large sample sizes. This multicenter study aims to providing a
80 comprehensive description of viral kinetic characteristics about Omicron BA.2 among patients
81 with a wide disease spectrum ranging from asymptomatic to critically ill or death, and to
82 identify the possible risk factors affecting viral characteristics.

83

84 **Methods**

85 **Study design and participants**

86 The study enrolled a total of 48830 COVID-19 cases, where all patients were admitted to the
87 three designated hospitals/makeshift hospitals in Shanghai from 23 March to 15 May 2022,
88 and their RT-PCR testing results were collected during the hospitalization. For each
89 participant, serial samples of nasopharyngeal swabs were collected from all the participants
90 during the hospitalization according to clinical need. Clinical information such as the
91 vaccination history, including the vaccination dates and vaccine type, the date of illness onset,
92 and duration of hospitalization were well documented from clinical records. Personal
93 demographic information was also obtained from the questionnaire reported by patients or
94 guardians.

95 COVID-19 cases were defined as individuals who tested positive for SARS-CoV-2 by
96 RT-PCR. The degree of severity of the patient was categorized according to the clinical
97 manifestation and the supportive measures used within the healthcare system according to a

98 revised WHO clinical progression scale¹⁸. Specifically, the asymptomatic type had no clinical
99 symptoms and no pneumonia manifestation can be found in imaging. The mild-moderate type
100 had clinical symptoms or shows abnormalities in lung imaging and received no oxygen
101 therapy. Patients who received oxygen therapy by mask or prongs, or received non-invasive
102 ventilation (NIV) or high flow oxygen therapy would be categorized as severe type. Those who
103 received intubation and mechanical ventilation or even died were defined as 'Critical-death'
104 patients.

105

106 **Laboratory confirmation of COVID-19 by reverse-transcription polymerase chain** 107 **reactions**

108 The sampling and detection procedure was described in supplementary material. The (Ct)
109 values of both ORF1ab and N genes of SARS-CoV-2 were collected but results are presented
110 only for N gene since the patterns observed for both genes were similar (unpublished data).
111 The Ct values of real-time RT PCR tests of nasopharyngeal species were used as surrogates
112 of relative viral genomic loads, and Ct ≤ 35 was considered positive. The viral load level was
113 inversely correlated with Ct value which is a low viral load characterized by a high Ct and a
114 high viral load characterized by low Ct values. Additionally, several researches revealed that
115 the cultural positive proportion of omicron virus from respiratory tract specimens was under 5%
116 with Ct value of 32^{16, 19-23}, proving the unsuccessful to recover infectious virus when Ct value

117 of 35. Thus, we chose the Ct value of 35 as positive threshold to exploring the correlation

118 between CT value and infectiveness in our study.

119

120 **Statistical analysis**

121 Demographic information including age, gender, status of underlying disease, vaccination

122 history at admission of patients was described in total as well as by clinical severity. Baseline

123 characteristics among four clinical severity groups was compared using Chi-square test for

124 discrete variables and the Wilcoxon test for continuous variables.

125 The kinetic of viral load of patients since initial detection was described by total, by clinical

126 severity, by age groups, by vaccination status, and by comorbidities using mean and 95%

127 confidence interval (CI). Virus shedding time (VST) was defined as the interval between the

128 date of initial detection of PCR and the date of subsequent first negative PCR test. For

129 patients with a positive result at their last follow-up, VST was right censor and was defined as

130 the interval between the date of the first positive PCR test and date of the last positive test.

131 The intervals of VST, intervals between symptom onset and first PCR positive, and the

132 intervals between symptom resolution and first PCR positive were estimated using gamma,

133 Weibull, and lognormal distributions based on AIC considering censor data. The median and

134 interquartile range (IQR) were described for each interval.

135 The viral proliferation stage and viral clearance stage were classified by the peak

136 concentration of viral load, with the former is the phase before peak and the latter is the phase

137 after peak. Thus, peak concentration of viral load and VST were described as essential index
138 of the kinetic by total and by several factors mentioned above respectively. Multivariate linear
139 regression and interval regression were used to investigate the risk factors associated with
140 peak Ct value and VST. The patients with long VST (> 30 days) were excluded in baseline
141 analysis. The comparison of baseline characteristics between participants and excluded
142 patients was conducted. The statistical analyses were conducted by R (version 4.14).

143

144 **Results**

145 As of May 15th, 2022, 48830 participants were included, with 31% of asymptomatic
146 participants, 68% of mild-moderate cases, 1% severe cases, 0.29% of critical cases or death
147 cases, respectively. The baseline characteristics of participants at admission were described
148 by clinical status in table 1. The median age was 45 years old (IQR, 32-55 years) and 63% of
149 participants were female. 21% of patients had at least one comorbidity, with hypertension
150 (14%), diabetes (5%) and cardiovascular diseases (2%) being the top three comorbidities.
151 The majority (88%) of patients had at least one-dose vaccination. Patients with severity of
152 severe or above were older and with more comorbidities, but less vaccination coverage than
153 asymptomatic and mild-moderate cases ($p<0.001$). The excluded patients had worsened
154 clinical severity status but similar gender proportion and age distribution comparing to the
155 participants (table S1).

156 **Viral shedding dynamic and viral load concentration**

157 On the day of initial detection 57% of patients were positive with an average Ct value of 33 (95%
158 CI, 31-34). This data remained stable within the first 4 days, before the viral load declined
159 significantly on an average of 6.1 days (IQR, 4.0-8.8 days), and slowly decreased further
160 within the next 3 weeks (Fig. 1A, B). The corresponding negative proportion would also gently
161 approach 100% after a rapid growth to 74% (95% CI, 73-74) by day 10 (Fig. 1A). The peak
162 occurrence of viral concentrations was within the first 4 days (IQR, 3-6 days) with a median Ct
163 value of 27.5 (IQR, 23.4-32.1) (Fig. 1C).

164 **Severity-specific viral shedding dynamic**

165 Patients with worsened clinical severity were observed to have higher viral loads with average
166 Ct values of 35 (95% CI, 33-37), 32 (95% CI, 27-40), 27 (95% CI, 20-34) for asymptomatic
167 cases, mild-moderate, and severe patients, respectively, on the initial detection day, and 21
168 (95% CI, 20-27) for critical patients one day since initial detection ($p < 0.001$). As the virus
169 was cleared, this superiority decreased with similar Ct values among the four groups after 24
170 days, except for similar Ct values between severe and critical groups during 0-5 days (Fig.
171 2A). The viral load of patients in the critical group showed a monotonically diminishing from a
172 Ct value of 21 to 38 (95% CI, 37-40) with the longest viral shedding duration of 14.5 days (IQR,
173 7.9-23.4) compared to other groups. Conversely, for asymptomatic, mild-moderate, and
174 severe cases, the average viral load was stable or significantly increasing within 4, 2, and 4
175 days, respectively, then dropped significantly with corresponding Ct values turning negative

176 by day 5.2 (IQR: 3.2-8.0), 6.4 (IQR: 4.4-9.0), and 12.7 (IQR: 8.6-17.1). For patients with
177 positive Ct values, the times of peak Ct value occurrence were similar among different groups
178 (4-5 days), but peak concentrations showed gradual differences among the four clinical
179 severity groups ($p < 0.001$) (Fig. 2C).

180 **Age-specific viral shedding dynamic**

181 Age-specific viral shedding dynamics revealed that elder patients had higher viral load and a
182 longer viral shedding duration than the youngsters during most days of viral shedding,
183 despite the lack of significant grade trend for four age groups in the first days (Fig. 2). On the
184 initial detection day, the Ct value of the 60-79 years old group was lower than that of the 80+
185 years old group (25, 95% CI: 21-28; 30, 95% CI: 24-36, $p = 0.185$), and was similar between
186 the other age groups (33, 95% CI: 32-34 on day 1; 34, 95% CI: 34-36 on day 0, $p = 0.366$).
187 Patients aged 80+ years old had the highest viral load, which increased within the first 4 days
188 followed by a gentle decrease before conversion by day 9.8 (IQR, 5.9-14.6). Patients aged
189 18-59 and 60-79 years old experienced a VST of 6.2 days (IQR, 4.0-8.8) and 6.9 days (IQR,
190 4.4-10.2), respectively. In contrast, patients under 18 years old had a shortest shedding
191 duration of 5.6 days (IQR, 3.6-8.3). Moreover, for patients with positive CT values, the time of
192 peak CT value occurrence was similar among different groups (4-5 days), but peak viral
193 concentrations showed an increasing trend with age ($p < 0.001$). The results of viral shedding
194 dynamic stratified by age and clinical severity were described in supplementary material.

195 **Factors associated with reduction in peak viral load and durations of viral shedding**
196 **time**

197 According to the multivariate analysis, higher peak viral concentrations and longer durations
198 of effective viral shedding were observed in unvaccinated cases, those of older age, and with
199 comorbidities (Fig. 4). Hypertension, kidney disease (especially kidney dialysis and kidney
200 transplantation), neurological conditions, rheumatism and psychotic conditions were
201 significantly correlated with higher peak viral load concentrations. Receiving at least one-dose
202 vaccination was significantly associated with a reduction in peak viral load and a shorter viral
203 shedding duration compared to the unvaccinated group. Sequential booster immunization
204 was found to be more effective in reducing peak viral load and shortening viral shedding
205 duration than homologous booster immunization, regardless of the type of vaccine
206 (inactivated, ad-vectored, or protein subunit). Stratified analyses by clinical severity were
207 reported in the supplementary material.

208 **Relationship between infectivity and symptomatic status.**

209 Figure 5 illustrated the clinical severity-specific kinetic of positive proportion among patients
210 since initial detection. Asymptomatic cases had a positive proportion of 34-39% within 6 days
211 since initial detection, which decayed to 12% (95%CI: 10-15) after two weeks. For
212 symptomatic cases, virus had already proliferation before symptom onset with lead times of
213 2.99, 1.56, and 2.13 days, resulting in high positive proportion of 63-66%, 67-85%, and 100%
214 before onset for mild-moderate, severe, and critical or death patients, respectively. For

215 mild-moderate and severe patients, the proportion decayed significantly as symptom
216 subsided. Mild-moderate patients decreased to 27% (95%CI: 26-28) on the day of symptom
217 resolution and below 20% after 14 days, while severe cases decayed to 76% (95%CI:70-80)
218 on the day of symptom resolution and below 20% after 24 days. In the critical or death group,
219 positive proportion maintained above 70% even after symptom resolution, until 20-30 days
220 when it decreased to 46% (95%CI: 37-55).

221

222

223 **Discussion**

224 Here we provided a comprehensive description of the characteristics of Omicron BA.2 viral
225 shedding across a wide range of disease spectra and age groups, using Ct value as a
226 surrogate of viral load. Among 48830 participants, 57% were PCR test positive on the initial
227 detection day, and viral load then increased significantly to peak at around 4 days after
228 detection following a decreasing trend with a VST of 6.1 days. Clinical severity and age had a
229 clear influence on the viral shedding dynamics, as evidenced by the initial Ct value, peak Ct
230 value and viral shedding duration, although the peak times were similar at 4-5 days.

231

232 It's important to note that the study participants were from the general population and couldn't
233 be representative of immunocompromised individuals. Additionally, the viral load dynamic for
234 the overall study population was relatively low and shedding quickly due to the large

235 proportion of asymptomatic and mild-moderate cases with lower viral loads. Compared to the
236 limited results on Omicron, our findings regarding the initial Ct value were similar to
237 observations of adolescent children^{24, 25}, adults²⁶ and elderly patients²⁷. Few studies have
238 reported the severity-specific Omicron viral load, and the participants in these studies had
239 different compositions of clinical severity^{11, 15}. Lin' study focus on the effect of vaccines and it's
240 hard to compare their results with this study¹¹. The initial Ct value of asymptomatic and mild
241 cases was higher than Yang' s study, which may be explain by the earlier isolation in our
242 study. The initial Ct value of asymptomatic cases was similar to Wu's study, while the Ct value
243 of symptomatic patients was relatively higher than that, which may be due to the high
244 consistence of fatal cases in their study and the 2-day delay in specimen collection since
245 onset²⁸. The peak viral load of mild-moderate patients in our study was similar to Hay's study
246^{15, 29}. The average peak times reported were 2.5-4.2 days since detection and 3-4 days since
247 onset^{15, 21, 30, 31}, and the viral load turned negative after 6-8 days, which could be prolonged to
248 more than 10 days with older ages^{17, 28, 32}. These results were similar to our findings. In
249 addition, the Ct value both at initial and the peak viral load stage in our study were higher than
250 those of ancestral, Alpha, and Delta variant in the same population^{28, 29, 33, 34}. This
251 phenomenon has been frequently observed^{1, 19, 20}, indicating that high transmissibility of
252 Omicron may be attributed to other mechanisms beyond viral load.
253
254 Accordingly, the overall Omicron infected individuals exhibited high viral load within the first

255 week since initial detection indicating the highest infectious ability in the first week, a 14-day
256 quarantine for infected people was an effective control as prior conducted³⁵. The probability of
257 infectious among asymptomatic cases was lowest during shortest infection duration
258 comparing to symptomatic cases. For mild-moderate cases, the infectious probability had
259 decayed to low level (20%) after symptom resolution. In the contrast, severe or above patients
260 had extreme high infectious proportion during more than 24 days infectious durations and
261 more than half of severe or above patients were still infectious after symptom resolution.
262 Despite the relaxation of national COVID-19 control measures in many countries, certain
263 institutions and workplaces, such as aging healthcare facilities, schools, and border entry
264 points, require ongoing vigilance with respect to the virus. For these settings, we would
265 recommend implementing graded control measures that take into account the clinical severity
266 and updating the duration of isolation or self-monitoring accordingly to reduce the impact on
267 normal life.
268
269 According to our results, patients with worsened clinical outcomes featured a lower initial Ct
270 value post detection, peak value as well as longer shedding duration. Older age group,
271 unvaccination, with comorbidities including hypertension, kidney disease especially kidney
272 dialysis and kidney transplantation, neurological disorders, rheumatism, psychotic conditions
273 and females were both independent risk factors associated with higher peak viral
274 concentration as well as longer shedding duration, which were supported by previous
275 studies^{21, 36-39}. A delay or dysfunction in the initial triggering of the immune reaction led by

276 aging⁴⁰, and higher levels of angiotensin converting enzyme 2 in alveoli of older people⁴¹,
277 which is believed to be a receptor for novel coronaviruses, can partially explain the
278 phenomenon. Our results support that getting at least one dose of vaccination and getting
279 mixed booster could effectively reduce the peak viral load and shorten the shedding duration
280 than unvaccinated patients.

281

282 Virus had proliferation preceding symptom onset and exhibited fastest replication in the first
283 4-5 days since detection, implying the requirement of antiviral therapy in early phase.
284 Previous study indicated that the effect of nirmatrelvir/ritonavir treatment had minor clinical
285 effect if practiced later than 5 days after onset⁴², and Paxlovid lacked efficacy for severe adult
286 patients in preventing illness progressing⁴³. Considering the delay of onset and detection,
287 according our study, it is recommended giving timely antiviral drug within 3 days since onset
288 for mild-moderate patients, which may play better effect on decrease peak level to shorten
289 shedding duration and deduce risk developing severe outcome, particularly for high-risk
290 group.

291

292 This study is the most comprehensive dynamic description about the viral shedding
293 characters of omicron in Shanghai outbreak, 2022 covering all age groups and wide disease
294 spectra with a sample size of over 40,000. In this study, we provided a comprehensive
295 depiction of viral shedding pattern stratified by clinical severity, age groups, number of
296 comorbidities, and vaccination status, and a quantified analysis to investigate the independent

297 risk factors associated viral shedding characters and estimation the effect. However, there are
298 still some weaknesses in our study. Firstly, this is a site-selection study, although the
299 large-sample size, the participants could not represent the entire population in Shanghai,
300 China. Secondly, the clinical diagnosis information on admission was incompletely collected
301 making it impossible to respond the relationship between symptom progression and viral load
302 dynamic in individual level. Thirdly, due to unavoidable reasons, the outcome of viral
303 conversion for critical or death groups was more likely censored, resulting in fluctuation in Ct
304 dynamic in the later phase of onset and wide confidence interval of VST estimation.

305

306 This study found that using Ct value as the proxy viral load, the viral load dynamic of Omicron
307 infected individuals presented considerable age variation and clinical severity variation. For
308 some specific workplaces, such as aging healthcare facilities and schools, the graded control
309 measures should be recommended due to possible increased clinical severity. Initial Ct value
310 could forecast severe outcome. Unvaccinated older people over 60 years of age with specific
311 comorbidities are the high-risk groups associated with higher viral load and longer shedding
312 duration. People with mild-moderate symptoms were less contagious after symptom
313 resolution, but for severe or above patients, contagious characteristics could sustain for more
314 than 1 week. To prevent worsened consequences, timely using of antiviral drugs within 3 days
315 since onset was recommended targeting mild-moderate patients.

316

317 **Ethics approval**

318 This study was performed in compliance with an institutional review board protocol at
319 Huashan Hospital (KY2022-596). Written informed consent was obtained from each
320 participant.

321 **Availability of data and materials**

322 The data analyzed are not publicly available as they contain personal information.

323 **Funding**

324 This work was supported by Shanghai Municipal Science and Technology Major
325 Project [HS2021SHZX001], the Key Program of the National Natural Science Foundation of
326 China [82161138018 and 82041010], Shanghai Science and Technology Committee
327 [20dz2260100, 20Z11901100] and Shanghai Hospital Development Center
328 [SHDC2020CR5010-002] and the Key Program of the National Science Foundation of China
329 [82130093].

330 **Authors' contributions**

331 Conception or design of the work: HJY, WHZ
332 Data collection: YL, JWA, SJG, HCZ, JPC, HYW, FS, YPW, JXZ, YW, RL, ZF, YLZ, XZ,
333 XYYX, XMY, YCZ

334 Data analysis and interpretation: JXZ, JWA, YL, FS, SJG, HCZ

335 Drafting the article: JXZ, JWA, YL

336 Critical revision of the article: HJY, WHZ, JXZ, JWA, YL, FS, SJG, HCZ, JJZ

337 Final approval of the version to be published: All of the authors.

338 **Acknowledgements**

339 Hongjie Yu acknowledges financial support from the Key Program of the National Natural

340 Science Foundation of China (82130093). Wenhong Zhang, Juanjuan Zhang acknowledge

341 financial support from Shanghai Municipal Science and Technology Major Project

342 (HS2021SHZX001). Wenhong Zhang acknowledges financial support from the Key Program

343 of the National Natural Science Foundation of China (82161138018 and 82041010),

344 Shanghai Science and Technology Committee (20dz2260100, 20Z11901100) and Shanghai

345 Hospital Development Center (SHDC2020CR5010-002). We thank all physicians and patients

346 for participating in this study. We appreciate all volunteers for helping collect data.

347

348

349 **Figure legend**

350 **Fig1. Characteristics of viral shedding of total participants.** (A) Ct value and negative
351 proportion at each time point since initial detection. Solid and dashed lines indicate average
352 Ct value and proportion, respectively. Grey shadow indicates 95%CI. (B) Time distribution of
353 viral shedding duration. Vertical dashed line indicates median of viral shedding time. (C)
354 Correlation between peak Ct value and the time to reach peak since initial detection. Blue
355 dashed lines indicate median of time at peak and the median of peak Ct value.

356 **Fig 2. Clinical severity-specific characteristics of viral shedding.** (A) Ct value at each
357 time point since initial detection. Solid line indicates average Ct value, shadow indicates 95%
358 CI. (B) Time distribution of viral shedding duration. Vertical dashed line indicates median of
359 viral shedding time. (C) Correlation between peak Ct value and the time to reach peak since
360 first positive PCR test. Vertical dashed line indicates median of time at peak and the median
361 of peak Ct value.

362 **Fig 3. Age group-specific characteristics of viral shedding.** (A) Ct value at each time point
363 since first positive PCR test. Solid line indicates average Ct value, shadow indicates 95% CI.
364 (B) Time distribution of viral shedding duration. Vertical dashed line indicates median of viral
365 shedding time. (C) Correlation between peak Ct value and the time to reach peak since first
366 positive PCR test. Vertical dashed line indicates median of time at peak and the median of
367 peak Ct value.

368 **Fig 4. Risk factors associated with peak viral load (A) and viral shedding duration (B).**

369 The coefficients (dots) and 95% confidence intervals (95% CIs, line segments) were

370 estimated from a multivariable regression analysis with an adjustment for gender, age, and
371 comorbidities, and vaccination-infection status. Regression coefficients along with 95% CIs
372 are reported as solid dots and horizontal lines relative to the value of the regression intercept.
373 * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

374 **Fig 5. Clinical severity-specific progression of positive proportion from initial detection**

375 **along with symptom statuses.** A: asymptomatic group; B: mild-moderate group; C: severe
376 group; D: clinical or death group. The above margined figure is the density of time intervals
377 between symptom onset since initial PCR detection (red) and the symptom resolution since
378 initial PCR detection (blue). The vertical dashed lines represented the median of time of onset
379 and symptom resolution date since initial detection. *: aggregated 20-30 days into a group,
380 other time points were not treated.

381 **Table**

382 Table 1. Baseline characteristics of enrolled participants by clinical severity.

Characteristics	Total (n=48830)	Asymptomatic (n=15165, 31%)	Mild-moderate (n=33038, 68%)	Severe (n=487, 1%)	Critical or death (n=140, 0.29%)	P value
Gender						<0.001
Female	30664 (63)	10081 (66)	20220 (61)	271 (56)	92 (66)	
Male	18166 (37)	5084 (34)	12818 (39)	216 (44)	48 (34)	
Age (years)						<0.001
Median (IQR)	45 (32-55)	47 (34-56)	43 (32-54)	73 (65-85)	78 (69-89)	
0-17	1811 (4)	565 (4)	1245 (4)	1 (0)	0 (0)	
18-59	39836 (82)	11975 (79)	27779 (84)	66 (14)	16 (11)	
60-79	6536 (13)	2480 (16)	3750 (11)	249 (51)	57 (41)	
80+	647 (1)	145 (1)	264 (1)	171 (35)	67 (48)	
Comorbidities						<0.001
None	38093 (78)	12166 (80)	25871 (78)	51 (10)	5 (4)	
Hypertension	6872 (14)	1973 (13)	4481 (14)	317 (65)	101 (72)	
Diabetes	2336 (5)	708 (5)	1397 (4)	164 (34)	67 (48)	
Cardiovascular disease	1054 (2)	227 (1)	642 (2)	117 (24)	68 (49)	

Hematologic diseases	80 (0)	11 (0)	55 (0)	10 (2)	4 (3)	
Kidney disease (Level1)	172 (0)	36 (0)	108 (0)	16 (3)	12 (9)	
Kidney dialysis (Level2)	215 (0)	29 (0)	77 (0)	80 (16)	29 (21)	
Kidney transplantation (Level3)	13 (0)	1 (0)	6 (0)	5 (1)	1 (1)	
					48 (34)	
Neurological conditions	412 (1)	99 (1)	187 (1)	78 (16)		
Pneumonia	522 (1)	91 (1)	390 (1)	38 (8)	3 (2)	
					0 (0)	
HIV	3 (0)	1 (0)	2 (0)	0 (0)		
					21 (15)	
Malignancy	345 (1)	54 (0)	227 (1)	43 (9)		
					8 (6)	
Liver disease	330 (1)	58 (0)	258 (1)	6 (1)		
					1 (1)	
Rheumatism	184 (0)	30 (0)	143 (0)	10 (2)		
					0 (0)	
Rhinitis	173 (0)	17 (0)	156 (0)	0 (0)		
					5 (4)	
Psychotic condition	86 (0)	23 (0)	56 (0)	2 (0)		
Smoking history	5096 (10)	1236 (8)	3827 (12)	31 (6)	2 (1)	
Other underlying disease	6524 (13)	1336 (9)	4738 (14)	332 (68)	133 (95)	
Missing	574 (1)	289 (2)	269 (1)	14 (3)	2 (1)	
Vaccination type						<0.001
Unvaccinated	5502 (11)	1823 (12)	3273 (10)	328 (67)	78 (56)	

Inactivated_Partial (1 dose)	1483 (3)	503 (3)	968 (3)	10 (2)	2 (1)	
Inactivated_Full (2 doses)	16848 (35)	5273 (35)	11516 (35)	54 (11)	5 (4)	
Inactivated_booster (3 doses)	22694 (46)	6804 (45)	15838 (48)	39 (8)	13 (9)	
Ad_Full (1 dose)	937 (2)	335 (2)	602 (2)	0 (0)	0 (0)	
Ad_booster (2 doses)	442 (1)	153 (1)	287 (1)	1 (0)	1 (1)	
Protein_Partial (<3 doses)	33 (0)	5 (0)	28 (0)	0 (0)	0 (0)	
Protein_Full (3 doses)	292 (1)	42 (0)	248 (1)	2 (0)	0 (0)	
Mixed_Partial/Full (2/3 doses)	12 (0)	3 (0)	9 (0)	0 (0)	0 (0)	
Mixed_Booster (3 doses)	13 (0)	4 (0)	9 (0)	0 (0)	0 (0)	
Missing	574 (1)	220 (1)	260 (1)	53 (11)	41 (29)	
Days since full vaccination						
(median, IQR)	320 (291, 346)	321 (294, 346)	319 (289, 346)	320 (298, 349)	328 (310,342)	<0.001
Days since boost vaccination						
(median, IQR)	113 (92, 137)	113 (93, 135)	112 (92, 137)	116 (93, 131)	119 (98, 133)	<0.001

383 All variables are expressed as n (%) except when indicated otherwise. IQR: interquartile range.

References

1 Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics.

Nature reviews Microbiology. 2023;21:147-61.

DOI:<https://doi.org/10.1038/s41579-022-00822-w>

2 Ling Y, Lu G, Liu F, Tan Y, Xu X, Wei D, et al. The Omicron BA.2.2.1

subvariant drove the wave of SARS-CoV-2 outbreak in Shanghai during spring

2022. Cell discovery. 2022;8:97.

DOI:<https://doi.org/10.1038/s41421-022-00468-1>

3 Commission SMH. The 177th press conference of COVID-19 in Shanghai.

2022.

4 Chen Z, Deng X, Fang L, Sun K, Wu Y, Che T, et al. Epidemiological

characteristics and transmission dynamics of the outbreak caused by the

SARS-CoV-2 Omicron variant in Shanghai, China: A descriptive study. Lancet

Reg Health West Pac. 2022;29:100592.

DOI:<https://doi.org/10.1016/j.lanwpc.2022.100592>

5 Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C, et al. Transmission, viral

kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in

Guangzhou, China. EClinicalMedicine. 2021;40:101129.

DOI:<https://doi.org/10.1016/j.eclinm.2021.101129>

- 6 Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh M, et al. Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). *Clinical infectious diseases* : an official publication of the Infectious Diseases Society of America. 2022;75:e1128-e36. DOI:<https://doi.org/10.1093/cid/ciab721>
- 7 Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. *The Lancet Infectious diseases*. 2020;20:656-7. DOI:[https://doi.org/10.1016/s1473-3099\(20\)30232-2](https://doi.org/10.1016/s1473-3099(20)30232-2)
- 8 Pujadas E, Chaudhry F, McBride R, Richter F, Zhao S, Wajnberg A, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. *The Lancet Respiratory medicine*. 2020;8:e70. DOI:[https://doi.org/10.1016/s2213-2600\(20\)30354-4](https://doi.org/10.1016/s2213-2600(20)30354-4)
- 9 Munker D, Osterman A, Stubbe H, Muenchhoff M, Veit T, Weinberger T, et al. Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients. *The European respiratory journal*. 2021;58. DOI:<https://doi.org/10.1183/13993003.02724-2020>
- 10 Jang J, Jeong H, Kim BH, An S, Yang HR, Kim S. Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea. *PLoS One*. 2023;18:e0290154. DOI:<https://doi.org/10.1371/journal.pone.0290154>
- 11 Lin Y, Wu P, Tsang TK, Wong JY, Lau EHY, Yang B, et al. Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected

with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective observational study. *Lancet Microbe*. 2023;4:e722-e31.

DOI:[https://doi.org/10.1016/S2666-5247\(23\)00146-5](https://doi.org/10.1016/S2666-5247(23)00146-5)

12 Fryer HR, Golubchik T, Hall M, Fraser C, Hinch R, Ferretti L, et al. Viral burden is associated with age, vaccination, and viral variant in a population-representative study of SARS-CoV-2 that accounts for time-since-infection-related sampling bias. *PLoS Pathog*. 2023;19:e1011461.

DOI:<https://doi.org/10.1371/journal.ppat.1011461>

13 Ravindran S, Gubbay JB, Cronin K, Sullivan A, Zygmunt A, Johnson K, et al. Association Between Cycle Threshold Value and Vaccination Status Among Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Cases in Ontario, Canada, in December 2021. *Open Forum Infect Dis*. 2023;10:ofad282.

DOI:<https://doi.org/10.1093/ofid/ofad282>

14 van Rossum C, Meijer C, van Weerdenburg IJ, Bowles EC, Rovers CP, Ten Oever J, et al. Low SARS-CoV-2 Cq values in healthcare workers with symptomatic COVID-19 infections, regardless of symptom severity, The Netherlands, January to August 2022. *Euro Surveill*. 2023;28.

DOI:<https://doi.org/10.2807/1560-7917.ES.2023.28.4.2300007>

15 Yang Y, Guo L, Yuan J, Xu Z, Gu Y, Zhang J, et al. Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.1.529): a prospective cohort study from Shenzhen, China. *Lancet Microbe*.

2023;4:e632-e41. DOI:[https://doi.org/10.1016/S2666-5247\(23\)00139-8](https://doi.org/10.1016/S2666-5247(23)00139-8)

16 Theaux C, Martin Y, Montoto Piazza L, Wenk G, Notaristefano G, Mino L, et al. Persistence of SARS-CoV-2 RNA shedding and infectivity in immunized population: Prospective study along different epidemiological periods in Argentina. PLoS One. 2023;18:e0285704.

DOI:<https://doi.org/10.1371/journal.pone.0285704>

17 Liu W, Gong F, Zheng X, Pei L, Wang X, Yang S, et al. Factors associated with prolonged viral shedding of SARS-CoV-2 Omicron variant infection in Shanghai: A multicenter, retrospective, observational study. J Med Virol. 2023;95:e29342. DOI:<https://doi.org/10.1002/jmv.29342>

DOI:<https://doi.org/10.1002/jmv.29342>

18 A minimal common outcome measure set for COVID-19 clinical research. The Lancet Infectious diseases. 2020;20:e192-e7.

DOI:[https://doi.org/10.1016/S1473-3099\(20\)30483-7](https://doi.org/10.1016/S1473-3099(20)30483-7)

19 Puhach O, Adea K, Hulo N, Sattonnet P, Genecand C, Iten A, et al.

Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Nature medicine. 2022;28:1491-500. DOI:<https://doi.org/10.1038/s41591-022-01816-0>

DOI:<https://doi.org/10.1038/s41591-022-01816-0>

20 Fall A, Eldesouki RE, Sachithanandham J, Morris CP, Norton JM, Gaston

DC, et al. The displacement of the SARS-CoV-2 variant Delta with Omicron:

An investigation of hospital admissions and upper respiratory viral loads.

EBioMedicine. 2022;79:104008.

DOI:<https://doi.org/10.1016/j.ebiom.2022.104008>

21 Takahashi K, Ishikane M, Ujije M, Iwamoto N, Okumura N, Sato T, et al.

Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron

Variant–Infected Vaccinees. *Emerging Infectious Diseases*. 2022;28:998-1001.

DOI:<https://doi.org/10.3201/eid2805.220197>

22 Bouton TC, Atarere J, Turcinovic J, Seitz S, Sher-Jan C, Gilbert M, et al.

Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications for timing of release from isolation: a longitudinal cohort study. *Clinical*

infectious diseases : an official publication of the Infectious Diseases Society of America. 2022. DOI:<https://doi.org/10.1093/cid/ciac510>

23 Utzon AN, Johansen IS, Bang LL, Pedersen RM, Andersen TE, Madsen

LW. Viral dynamics of SARS-CoV-2 in immunocompromised patients. *Clin*

Microbiol Infect. 2023;29:1087 e1- e3.

DOI:<https://doi.org/10.1016/j.cmi.2023.05.013>

24 Ergoren MC, Komurcu K, Tuncel G, Akan G, Ozverel CS, Dalkan C, et al.

Impact of SARS-CoV-2 Delta and Omicron variants on viral burden and cycle threshold in BNT162b2-vaccinated 12-18 years group. *Brazilian journal of*

microbiology : [publication of the Brazilian Society for Microbiology].

2022;53:1937-40. DOI:<https://doi.org/10.1007/s42770-022-00820-3>

25 Ao Y, Li J, Wei Z, Wang Z, Tian H, Qiu Y, et al. Clinical and virological

characteristics of SARS-CoV-2 Omicron BA.2.2 variant outbreaks during April to May, 2022, Shanghai, China. *Journal of Infection*. 2022;85:573-607.

DOI:<https://doi.org/10.1016/j.jinf.2022.07.027>

26 Wu Q, Shi L, Li H, Huang S, Li H, Li L, et al. Viral RNA Load in Symptomatic and Asymptomatic COVID-19 Omicron Variant-Positive Patients. *Can Respir J*. 2022;2022:5460400. DOI:<https://doi.org/10.1155/2022/5460400>

27 Woodbridge Y, Amit S, Huppert A, Kopelman NM. Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection. *Nature Communications*. 2022;13:6706. DOI:<https://doi.org/10.1038/s41467-022-33096-0>

28 Wu P, Lin Y, Tsang T, Wong J, Lau E, Yang B, et al. Viral shedding among symptomatic COVID-19 cases infected with the ancestral strain and Omicron BA.2. *Research Square*; 2022.

29 Hay JA, Kissler SM, Fauver JR, Mack C, Tai CG, Samant RM, et al. Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study. *eLife*. 2022;11:e81849. DOI:<https://doi.org/10.7554/eLife.81849>

30 Choi G, Lim AY, Choi S, Park K, Lee SY, Kim JH. Viral shedding patterns of the symptomatic SARS-CoV-2 infection according to virus-type dominant periods and vaccination status in Gyeonggi Province, Korea. *Epidemiology and health*. 2022:e2023008. DOI:<https://doi.org/10.4178/epih.e2023008>

31 Kandel C, Lee Y, Taylor M, Llanes A, McCready J, Crowl G, et al. Viral dynamics of the SARS-CoV-2 Omicron Variant among household contacts with 2 or 3 COVID-19 vaccine doses. *J Infect*. 2022;85:666-70. DOI:<https://doi.org/10.1016/j.jinf.2022.10.027>

32 Selvavinayagam ST, Yong YK, Joseph N, Hemashree K, Tan HY, Zhang Y, et al. Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants. *Frontiers in public health*. 2022;10:1018399.

DOI:<https://doi.org/10.3389/fpubh.2022.1018399>

33 Tassetto M, Garcia-Knight M, Anglin K, Lu S, Zhang A, Romero M, et al. Detection of Higher Cycle Threshold Values in Culturable SARS-CoV-2 Omicron BA.1 Sublineage Compared with Pre-Omicron Variant Specimens - San Francisco Bay Area, California, July 2021-March 2022. *MMWR Morbidity and mortality weekly report*. 2022;71:1151-4.

DOI:<https://doi.org/10.15585/mmwr.mm7136a3>

34 von Wintersdorff CJH, Dingemans J, van Alphen LB, Wolffs PFG, van der Veer BMJW, Hoebe CJPA, et al. Infections with the SARS-CoV-2 Delta variant exhibit fourfold increased viral loads in the upper airways compared to Alpha or non-variants of concern. *Scientific Reports*. 2022;12:13922.

DOI:<https://doi.org/10.1038/s41598-022-18279-5>



35 China NHCotPsRo. Protocol for Prevention and Control of the Novel Coronavirus Pneumonia (eighth edition). 2021.

36 Okita Y, Morita T, Kumanogoh A. Duration of SARS-CoV-2 RNA positivity from various specimens and clinical characteristics in patients with COVID-19: a systematic review and meta-analysis. *Inflammation and regeneration*. 2022;42:16. DOI:<https://doi.org/10.1186/s41232-022-00205-x>

- 37 Qassim SH, Chemaitely H, Ayoub HH, AlMukdad S, Tang P, Hasan MR, et al. Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections. *Journal of travel medicine*. 2022;29. DOI:<https://doi.org/10.1093/jtm/taac068>
- 38 Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. *The Lancet Infectious diseases*. 2022;22:183-95. DOI:[https://doi.org/10.1016/s1473-3099\(21\)00648-4](https://doi.org/10.1016/s1473-3099(21)00648-4)
- 39 Wu J, Chen M, Tu C, Xiao Q, Liu X, Zhou X, et al. Clinical Course and Factors Associated with Viral RNA Shedding and Radiologic Resolution in Patients with COVID-19: a Retrospective Study. *Clinical laboratory*. 2022;68. DOI:<https://doi.org/10.7754/Clin.Lab.2021.210605>
- 40 Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E. SARS-CoV-2, COVID-19 and the aging immune system. *Nature Aging*. 2021;1:769-82. DOI:<https://doi.org/10.1038/s43587-021-00114-7>
- 41 Kaseb AO, Mohamed YI, Malek AE, Raad, II, Altameemi L, Li D, et al. The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection. *Pathogens (Basel, Switzerland)*. 2021;10. DOI:<https://doi.org/10.3390/pathogens10030379>
- 42 Li H, Gao M, You H, Zhang P, Pan Y, Li N, et al. Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute

Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase
Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among
High-Risk Patients With Coronavirus Disease 2019 (COVID-19). *Clinical
infectious diseases* : an official publication of the Infectious Diseases Society
of America. 2023;76:e148-e54. DOI:<https://doi.org/10.1093/cid/ciac600>

43 Liu J, Pan X, Zhang S, Li M, Ma K, Fan C, et al. Efficacy and safety of
Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter
randomized controlled study. *The Lancet Regional Health - Western Pacific*.
2023:100694.
DOI:<https://doi.org/https://doi.org/10.1016/j.lanwpc.2023.100694>

A**B****C**